Clinical trial
A Stratified Sickle Event Randomized Trial (ASSERT)
NCT00102791 · Icagen, Industry · Terminated
Key facts
| NCT number | NCT00102791 |
|---|---|
| Title | A Stratified Sickle Event Randomized Trial (ASSERT) |
| Official title | A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months |
| Acronym | ASSERT |
| Lead sponsor | Icagen, Industry |
| Collaborators | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | ICA-17043 |
| Enrollment | 297 |
| Start date | Feb 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Feb 2, 2005 |
| Last update posted | Mar 27, 2008 |
| Countries | Brazil, France, Jamaica, Trinidad and Tobago, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: